直接口服抗凝药的检测与监测
直接口服抗凝药(DOAC)已获批作为非瓣膜性心房颤动卒中预防和静脉血栓栓塞症治疗的一线用药,常规无需监测。但在致命性出血或紧急手术等关键临床情境下,DOAC 水平检测可能有用;DOAC 特异性检测已开发但可及性有限,尚需进一步研究其临床作用。
要点
- DOAC 因治疗窗宽、药物相互作用少,常规无需检测水平。
- 致命性出血或需紧急手术时,DOAC 检测可能有用,尤其是有逆转剂时。
- DOAC 特异性检测已开发但可及性有限,尚无获批检测。
核心结论
- DOAC 已获批为包括非瓣膜性心房颤动卒中预防和静脉血栓栓塞症治疗在内适应症的一线治疗。
- 在致命性出血或需紧急手术等关键临床情境下,DOAC 检测可能有用,尤其是有 DOAC 逆转剂可用时。
- 需要进一步研究 DOAC 检测的作用,以探索其在临床实践中的全部潜力和角色。
研究设计与样本
- 原文为综述,未报告系统检索范围与样本量。
主要发现
- DOAC 与标准治疗维生素 K 拮抗剂和低分子量肝素相比,疗效和安全性结局相似或更好,且门诊使用更便捷。
- DOAC 为口服制剂,给药方案简单、半衰期短,治疗窗宽且药物相互作用有限,无需检测水平。
- 常规凝血试验的现有使用指南虽有,但这些试验不足以提供最优诊疗。
- DOAC 特异性检测已开发,但在欧洲可及性有限,在美国可及性更低,且均未获批。
关键数值与推荐
- 原文未报告具体检测阈值或推荐等级。
临床怎么用
- DOAC 检测可能在致命性出血或需紧急手术等关键临床情境中有用,尤其是有 DOAC 逆转剂可用时。
- 具有超出正常范围特征的患者可能从 DOAC 检测提供的指导中获益。
局限性
- DOAC 特异性检测可及性有限,在欧洲有限,在美国更低,且均未获批。
- 常规凝血试验不足以提供最优诊疗。
- 采用 DOAC 检测的障碍包括检测可靠性和人员成本,但这些问题正在迅速解决。
- 需要进一步研究 DOAC 检测的作用,以探索其在临床实践中的全部潜力和角色。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Direct oral anticoagulants (DOACs) have significantly improved the care of patients requiring anticoagulation. With similar or better efficacy and safety outcomes and easier use in the outpatient setting compared with the standard-of-care vitamin K antagonists and low molecular weight heparin, DOACs are now endorsed as first-line treatment of indications including prevention of stroke and systemic embolism in nonvalvular atrial fibrillation and treatment of venous thromboembolism. DOACs are easy-to-use oral agents that offer simple dosing and short half-lives, with no need to test levels because of the wide therapeutic window and limited drug-drug interactions. After almost a decade of DOAC use, the question of testing DOAC levels in certain clinical situations has become the focus of debate. Although guidance for using routine coagulation tests is available, these tests are inadequate for optimal care. DOAC-specific tests have been developed but have limited availability in Europe and less availability in the United States. None are licensed. DOAC testing may be useful in the setting of critical clinical situations such as life-threatening bleeding or need for emergent surgery, especially with the availability of DOAC reversal agents. Patients with characteristics that fall outside the normal range may benefit from the guidance that DOAC testing could offer. Obstacles to adopting DOAC testing have been raised, such as test reliability and staffing costs; however, these problems are rapidly being resolved. Further investigation of the role of DOAC testing is needed to explore its full potential and role in clinical practice.
引用
- Connors JM. Testing and monitoring direct oral anticoagulants. Blood. 2018. PMID: 30201757. doi:10.1182/blood-2018-04-791541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。